{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:06:02Z","timestamp":1787162762856,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.eururo.2013.04.020","type":"journal-article","created":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T06:11:43Z","timestamp":1366351903000},"page":"722-730","source":"Crossref","is-referenced-by-count":52,"title":["Intermittent Androgen-deprivation Therapy in Prostate Cancer: A Critical Review Focused on Phase 3 Trials"],"prefix":"10.1016","volume":"64","author":[{"given":"Alessandro","family":"Sciarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Anders","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Brausi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teuvo L.J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Calais da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.04.020_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","article-title":"Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature","volume":"57","author":"Abrahamsson","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0010","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N","article-title":"Intermittent endocrine therapy for advanced prostate cancer","volume":"58","author":"Klotz","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2013.04.020_bib0015","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology Web site. http:\/\/www.uroweb.org\/gls\/pdf\/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf."},{"key":"10.1016\/j.eururo.2013.04.020_bib0020","first-page":"2275","article-title":"Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma","volume":"50","author":"Bruchovsky","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2013.04.020_bib0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0960-0760(96)00018-0","article-title":"Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model","volume":"58","author":"Sato","year":"1996","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0030","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z","article-title":"Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate specific antigen","volume":"71","author":"Akakura","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2013.04.020_bib0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/pros.10222","article-title":"Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma","volume":"55","author":"Sciarra","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2013.04.020_bib0040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00345-009-0393-1","article-title":"A 16 year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results","volume":"27","author":"Prapotnich","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3816\/CGC.2002.n.018","article-title":"Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-na\u00efve prostate cancer: results of a prospective randomize multicentre trial","volume":"1","author":"De Leval","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.eururo.2013.04.020_bib0050","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group","volume":"52","author":"Calais da Silva","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0055","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2012.01.122","article-title":"The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer","volume":"187","author":"Salonen","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0195","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.eururo.2013.04.020_bib0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy [published correction appears in N Engl J Med 2012;367:2262]","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.04.020_bib0070","unstructured":"Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF. Continuous versus intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol. In press."},{"key":"10.1016\/j.eururo.2013.04.020_bib0075","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2012.11120.x","article-title":"Intermittent hormone therapy in the treatment of metastatic prostate cancer: a randomized trial","volume":"110","author":"Mottet","year":"2012","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.eururo.2013.04.020_bib0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1569-9056(03)80094-5","article-title":"Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy - first results of a randomised prospective phase-III clinical trial (AUO study AP06\/95)","volume":"2","author":"Tunn","year":"2003","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2013.04.020_bib0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0090","first-page":"1","article-title":"Intermittent androgen deprivation therapy: redefining the standard of care?","volume":"12","author":"Shore","year":"2010","journal-title":"Rev Urol"},{"issue":"8","key":"10.1016\/j.eururo.2013.04.020_bib0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eursup.2005.08.005","article-title":"Expert opinion on optimal testosterone control in prostate cancer","volume":"4","author":"Zlotta","year":"2005","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2013.04.020_bib0100","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0090-4295(00)00793-7","article-title":"Reassessment of the definition of castrated levels of testosterone: implications for clinical decision making","volume":"56","author":"Oefelein","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.04.020_bib0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/pros.21046","article-title":"Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model","volume":"70","author":"Wang","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2013.04.020_bib0110","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.urology.2007.09.033","article-title":"Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy","volume":"71","author":"Di Silverio","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.04.020_bib0115","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.juro.2008.11.026","article-title":"A double blind randomized crossover study of oral thalidomide versus placebo in patients with stage D0 androgen dependent prostate cancer following limited androgen ablation","volume":"181","author":"Figg","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0120","unstructured":"Oxford Centre for Evidence-based Medicine levels of evidence (March 2009). Centre for Evidence-based Medicine Web site. http:\/\/www.cebm.net\/index.aspx?o=1025."},{"key":"10.1016\/j.eururo.2013.04.020_bib0125","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1464-410X.2007.06770.x","article-title":"International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta analysis of 1446 patients","volume":"99","author":"Shaw","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.04.020_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005009.pub2","article-title":"Intermittent versus continuous androgen suppression for prostate cancer","author":"Conti","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl","key":"10.1016\/j.eururo.2013.04.020_bib0135","article-title":"Randomized prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5015]","volume":"25","author":"Miller","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2013.04.020_bib0140","article-title":"Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients: results of S9346 (INT-0162), an international phase III trial [abstract 4]","volume":"30","author":"Hussain","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0145","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.6004\/jnccn.2012.0114","article-title":"Prostate cancer, version 3.2012: featured updates to the NCCN guidelines","volume":"10","author":"Mohler","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2013.04.020_bib0150","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1442-2042.2012.03001.x","article-title":"Safety and tolerability of intermittent androgen deprivation therapy: a literature review","volume":"19","author":"Gruca","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2012.07.040","article-title":"Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects","volume":"63","author":"Salonen","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0160","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0302-2838(03)00004-6","article-title":"A 10-year clinical experience with intermittent hormonal therapy for prostate cancer","volume":"43","author":"Prapotnich","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.urolonc.2008.07.025","article-title":"The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer","volume":"27","author":"Gleave","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0170","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/pros.21377","article-title":"The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation","volume":"71","author":"Keizman","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2013.04.020_bib0175","unstructured":"Sciarra A, Cattarino S, Gentilucci A, et al. Predictors for response to intermittent androgen deprivation in prostate cancer patients with biochemical progression after surgery. Urol Oncol. In press."},{"key":"10.1016\/j.eururo.2013.04.020_bib0180","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1200\/JCO.2009.25.1330","article-title":"Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation","volume":"28","author":"Yu","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.04.020_bib0185","unstructured":"Prostate cancer. Guideline for the management of clinically localized prostate cancer: 2007 update. American Urological Association Web site. http:\/\/www.auanet.org\/content\/guidelines-and-quality-care\/clinical-guidelines\/main-reports\/proscan07\/content.pdf."},{"key":"10.1016\/j.eururo.2013.04.020_bib0190","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813003837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813003837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:02:18Z","timestamp":1715227338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813003837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0302283813003837"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.04.020","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718158960.793486357","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718158960.793489559","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}